All In Biotech

Drug Trial Radar · NCT01630083

Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer

A Randomized Phase II Multicenter, Open-Label Study Evaluating the Efficacy and Safety of IMAB362 in Combination With the EOX (Epirubicin, Oxaliplatin, Capecitabine) Regimen as First-Line Treatment of Patients With CLDN18.2-Positive Advanced Adenocarcinomas of the Stomach, the Esophagus or the Gastroesophageal Junction

Last checked: Nov 20, 2026Latest source record: Jun 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 252 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

252

Actual

Start

Jul 19, 2012

Primary completion

Jan 31, 2019

Study completion Jan 31, 2019

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Jun 28, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the trial is to assess the therapeutic effects and the safety profile of IMAB362 combined with EOX (epirubicin, oxaliplatin, capecitabine) as first-line treatment for patients with advanced adenocarcinoma of the stomach, the esophagus or the gastroesophageal junction compared to EOX alone. Furthermore, sufficient binding of IMAB362 to the target cells is necessary for antitumoral activity. Thus, two dose levels ensuring a serum level above the in vitro predicted clinical efficacy threshold will be investigated.

Conditions

  • CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
  • CLDN18.2-positive Adenocarcinoma of Esophagus
  • CLDN18.2-positive Gastric Adenocarcinoma

Interventions

  • epirubicinDrug

    Epirubicin will be administered at a dose of 50 mg/m\^2 as a 15-minute intravenous infusion on day 1 of each cycle.

  • oxaliplatinDrug

    Oxaliplatin will be administered at a dose of 130 mg/m\^2 as a 2-hour intravenous infusion on day 1 of each cycle.

  • capecitabineDrug

    The daily dose of capecitabine will be 1250 mg/m\^2. Capecitabine tablets to be given once daily at a dose of 625 mg/m\^2 orally in the evening of day 1 of each cycle and twice daily at a dose of 625 mg/m\^2 orally on days 2 to 21 of each cycle; the morning dose of capecitabine on day 1 of each cycle to be omitted due to administration of zolbetuximab, epirubicin and oxaliplatin.

  • zolbetuximabDrug

    Two different formats of zolbetuximab, comprising different strengths, to be provided. Vials contained 22 mg or 105 mg of zolbetuximab. Prior to administration, zolbetuximab will be reconstituted with 1.1 mL (22 mg zolbetuximab vials) or 5.0 mL (105 mg zolbetuximab vials) water for injection, which will result in a concentration of 20 mg/mL zolbetuximab. The extractable volume per vial will be 1 mL (for 22 mg zolbetuximab vials) or 5 mL (for 105 mg zolbetuximab vials). The reconstituted solution will be further diluted with sodium chloride 0.9% to a final concentration of 2 mg/mL zolbetuximab. Zolbetuximab will be administered as an intravenous infusion over 2 to 3 hours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: From randomization to the data cut-off date of 31JAN2019; maximum time on follow-up was, 68.2, 47.2 & 59.6 months in the EOX, EOX+Zolbetuximab 600 mg, and EOX+Zolbetuximab 1000 mg treatment groups respectively.
  2. Number of Participants with Adverse Events (AEs)Time frame: From the first dose of study drug administration up to 30 days after the last study medication administration (up to 1791 days).

Locations

48 sites in 6 countries. Site status is shown where the registry gives one.

  • Site BUL004

    Plovdiv, Bulgaria

  • Site BUL001

    Sofia, Bulgaria

  • Site BUL003

    Sofia, Bulgaria

  • Site BUL005

    Sofia, Bulgaria

  • Site BUL002

    Varna, Bulgaria

  • Site CZE002

    Olomouc, Czechia

  • Site CZE001

    Znojmo, Czechia

  • Site GER012

    Bielefeld, Germany

  • Site GER029-01

    Bochum, Germany

  • Site GER029

    Bochum, Germany

  • Site GER010

    Dresden, Germany

  • Site GER001

    Essen, Germany

  • Site GER017

    Frankfurt, Germany

  • Site GER005

    Halle, Germany

  • Site GER020

    Leipzig, Germany

  • Site GER016

    Münster, Germany

  • Site GER013

    Pinneberg, Germany

  • Site LAT001

    Liepāja, Latvia

  • Site LAT002

    Riga, Latvia

  • Site RUS011

    Arkhangelsk, Russia

  • Site RUS016

    Bryansk, Russia

  • Site RUS006

    Chelyabinsk, Russia

  • Site RUS007

    Ivanovo, Russia

  • Site RUS009

    Kursk, Russia

  • Site RUS001

    Moscow, Russia

  • Site RUS002

    Obninsk, Russia

  • Site RUS023

    Omsk, Russia

  • Site RUS014

    Orenburg, Russia

  • Site RUS012

    Oryol, Russia

  • Site RUS005

    Pyatigorsk, Russia

  • Site RUS019

    Ryazan, Russia

  • Site RUS003

    Saint Petersburg, Russia

  • Site RUS010

    Saint Petersburg, Russia

  • Site RUS015

    Saint Petersburg, Russia

  • Site RUS017

    Velikiy Novgorod, Russia

  • Site RUS013

    Yaroslavl, Russia

  • Site UKR003

    Dnipropetrovsk, Ukraine

  • Site UKR001

    Donetsk, Ukraine

  • Site UKR002

    Donetsk, Ukraine

  • Site UKR008

    Ivano-Frankivsk, Ukraine

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.